We have previously described a C-terminally truncated form of CPSF6 (CPSF6-358) that has potent antiviral activity against different HIV-1, HIV-2, and SIV isolates, but no activity against EIAV, FIV, or MLV. CPSF6-358 interferes with the nuclear entry of HIV-1. We selected for HIV-1 replication in cells expressing CPSF6-358 and identified a mutation of N74D of CA as sufficient to confer viral resistance. We examined the nuclear pore dependencies for wild-type (WT) and N74D HIV-1 and found that the isolates require some of the same pore proteins but differ in requirements for others. In particular, N74D HIV-1 was less sensitive to depletion of TNPO3 (a karyopherin), NUP153, and NUP358/RanBP2 than WT HIV-1. These experiments established a genetic interaction between HIV-1 CA and the nuclear pore. We are now attempting to define the route that HIV-1 takes to the nucleus: the cell factors it interacts with and how it interacts with these factors. Our data suggest a direct interaction of WT CPSF6 with CA. We have also discovered that TNPO3 regulates CPSF6 nuclear localization. We are examining whether CPSF6 normally interacts with HIV-1 CA in the cytoplasm and whether this interaction is important for nuclear entry of the virus. Although experiments with transformed cells have not revealed a role for endogenous CPSF6 in HIV-1 infection, experiments with primary macrophages suggest a positive role in HIV-1 infection. [Corresponds to KewalRamani Project 1 in the October 2011 site visit report of the HIV Drug Resistance Program]

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010487-11
Application #
8763115
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2013
Total Cost
$1,037,098
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Gres, Anna T; Kirby, Karen A; KewalRamani, Vineet N et al. (2015) STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability. Science 349:99-103
Maertens, Goedele N; Cook, Nicola J; Wang, Weifeng et al. (2014) Structural basis for nuclear import of splicing factors by human Transportin 3. Proc Natl Acad Sci U S A 111:2728-33
Koh, Yasuhiro; Wu, Xiaolin; Ferris, Andrea L et al. (2013) Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration. J Virol 87:648-58
Lee, Kyeongeun; Mulky, Alok; Yuen, Wendy et al. (2012) HIV-1 capsid-targeting domain of cleavage and polyadenylation specificity factor 6. J Virol 86:3851-60
Ambrose, Zandrea; Lee, KyeongEun; Ndjomou, Jean et al. (2012) Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol 86:4708-14
Price, Amanda J; Fletcher, Adam J; Schaller, Torsten et al. (2012) CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog 8:e1002896
Schaller, Torsten; Ocwieja, Karen E; Rasaiyaah, Jane et al. (2011) HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog 7:e1002439
Lee, KyeongEun; Ambrose, Zandrea; Martin, Thomas D et al. (2010) Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7:221-33
Krishnan, Lavanya; Matreyek, Kenneth A; Oztop, Ilker et al. (2010) The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J Virol 84:397-406
Furtak, Vyacheslav; Mulky, Alok; Rawlings, Stephen A et al. (2010) Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity. PLoS One 5:e9081